Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action
B Baron, Y Wang, SI Maehara, Y Maehara… - Anticancer …, 2015 - ar.iiarjournals.org
Background/Aim. The pancreatic cancer cell line KLM1 can gain chemoresistance following
gemcitabine (GEM) treatment. Metformin was found to be a useful sensitising agent towards …
gemcitabine (GEM) treatment. Metformin was found to be a useful sensitising agent towards …
[HTML][HTML] Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling
X Chai, H Chu, X Yang, Y Meng, P Shi, S Gou - Scientific reports, 2015 - nature.com
The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy
because of its high frequency of chemoresistance. Metformin is widely used to treat type II …
because of its high frequency of chemoresistance. Metformin is widely used to treat type II …
[PDF][PDF] Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway
HY Zhou, XM Yao, XD Chen, JM Tang… - Eur Rev Med …, 2019 - europeanreview.org
OBJECTIVE: To investigate the effect of metformin (MET) on enhancing the sensitivity of
human pancreatic cancer cells to gemcitabine (GEM) by regulating the phosphatidylinositol …
human pancreatic cancer cells to gemcitabine (GEM) by regulating the phosphatidylinositol …
[HTML][HTML] Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress
J Catapano, M Luty, T Wróbel, M Pudełek… - Cellular & Molecular …, 2022 - Springer
Background Metformin is an inhibitor of oxidative phosphorylation that displays an array of
anticancer activities. The interference of metformin with the activity of multi-drug resistance …
anticancer activities. The interference of metformin with the activity of multi-drug resistance …
A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines
S Mori-Iwamoto, Y Kuramitsu… - Molecular …, 2008 - spandidos-publications.com
Pancreatic cancer is one of the most highly fatal cancers and is generally resistant to
chemotherapy. Currently, gemcitabine appears to be the only effective agent for its treatment …
chemotherapy. Currently, gemcitabine appears to be the only effective agent for its treatment …
[HTML][HTML] Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response
R Crake, I Gasmi, J Dehaye, F Lardinois, R Peiffer… - Cells, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis.
Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major …
Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major …
[HTML][HTML] Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma
K Suzuki, O Takeuchi, Y Suzuki… - … journal of oncology, 2019 - spandidos-publications.com
Metformin (MET) is the first‑line treatment for type 2 diabetes mellitus. Several
epidemiological studies have suggested the potential anti‑cancer effects of MET, including …
epidemiological studies have suggested the potential anti‑cancer effects of MET, including …
Metformin influences drug sensitivity in pancreatic cancer cells
S Candido, SL Abrams, L Steelman… - Advances in biological …, 2018 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy
and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five …
and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five …
[HTML][HTML] Metformin induces cell cycle arrest and apoptosis in drug-resistant leukemia cells
A Rodríguez-Lirio, G Pérez-Yarza… - Leukemia research …, 2015 - hindawi.com
Recent epidemiological studies indicate that the antidiabetic drug metformin has
chemosensitizing and chemopreventive effects against carcinogenesis. Here, we …
chemosensitizing and chemopreventive effects against carcinogenesis. Here, we …
[HTML][HTML] Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin
D Zechner, F Bürtin, AC Albert, X Zhang, S Kumstel… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Cancer heterogeneity and microenvironmental aspects within a tumor are considered key
factors influencing resistance of carcinoma cells to distinct chemotherapeutical agents. We …
factors influencing resistance of carcinoma cells to distinct chemotherapeutical agents. We …